儿童代谢相关性脂肪肝的无创诊断研究进展

摘要/Abstract

摘要： 儿童代谢相关脂肪性肝病(MAFLD)作为与代谢紊乱相关的进展性肝病,在青少年中患病率显著上升,其无创诊断成为研究重点。本文总结了目前儿童MAFLD无创诊断技术的研究进展,强调影像学技术可量化评估脂肪沉积;血清学标志物(如Ⅳ型胶原蛋白及IL-1β、IL-6等细胞因子)能够反映疾病严重程度;组学研究有助于揭示病理机制并推动新型诊断工具的开发。此外,相比侵入性方法,无创性诊断模型具备非侵入性、操作简便、成本较低的优势;而新型呼气测试在早期筛查中亦展现出良好前景。本综述整合了当前无创诊断方法的临床证据,旨在为疾病的早期识别和动态监测提供参考。同时,我们强调,未来亟须在多维度技术上实现创新以进一步提升诊断的准确性和管理的有效性,从而更好地服务于临床实践并指引后续科研方向。

冯巩, 李如欣, 党焓悦, 李文彤, 弥曼, 陈敏, 严琴琴. 儿童代谢相关性脂肪肝的无创诊断研究进展[J]. 肝脏, 2025, 30(9): 1292-1295.

/ 推荐

参考文献

[1] Mǎrginean C O, Meli, L E, Sǎsǎran M O. Metabolic associated fatty liver disease in children-from atomistic to holistic [J]. Biomedicines, 2021, 9(12):1866.
[2] Le Garf S, Nègre V, Anty R, et al. Metabolic fatty liver disease in children: a growing public health problem [J]. Biomedicines, 2021, 9(12):1915.
[3] Fan J G, Li X Y. NAFLD renaming to MAFLD, MASLD: background, similarities, differences, and countermeasures [J].Chin J Hepatol, 2023, 31(8): 789-792.
[4] Viswanath A, Fouda S, Fernandez C J, et al. Metabolic-associated fatty liver disease and sarcopenia: a double whammy [J]. World J Hepatol, 2024, 16(2): 152-163.
[5] Kanwal F, Shubrook J H, Adams L A, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease [J]. Gastroenterology, 2021, 161(5): 1657-1669.
[6] Hwang J Y, Yoon H M, Kim J R, et al. Diagnostic performance of transient elastography for liver fibrosis in children: a systematic review and meta-analysis [J]. Ajr Am J Roentgenol, 2018, 211(5): 257-266.
[7] Caballería L, Pera G, Arteaga I, et al. High prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study [J]. Clin Gastroenterol Hepatol, 2018, 16(7): 1138-1145.
[8] Rehm J L, Wolfgram P M, Hernando D, et al. Proton density fat-fraction is an accurate biomarker of hepatic steatosis in adolescent girls and young women [J]. Eur Radiol, 2015, 25(10): 2921-2930.
[9] Petroff D, Blank V, Newsome P N, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis [J]. Lancet Gastroenterol Hepatol, 2021, 6(3): 185-198.
[10] Chen B R, Pan C Q. Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease [J]. Clin Res Hepatol Gastroenterol, 2022, 46(1): 101755.
[11] Jang J K, Choi S H, Lee J S, et al. Accuracy of the ultrasound attenuation coefficient for the evaluation of hepatic steatosis: a systematic review and meta-analysis of prospective studies [J]. Ultrasonography, 2022, 41(1): 83-92.
[12] Starekova J, Hernando D, Pickhardt P J, et al. Quantification of liver fat content with CT and MRI: state of the art [J]. Radiology, 2021, 301(2): 250-262.
[13] Kalarakis G, Perisinakis K, Akoumianakis E, et al. CT liver perfusion in patients with hepatocellular carcinoma: can we modify acquisition protocol to reduce patient exposure? [J]. Eur Radiol, 2021, 31(3): 1410-1419.
[14] Roberts N T, Hernando D, Holmes J H, et al. Noise properties of proton density fat fraction estimated using chemical shift-encoded MRI [J]. Magn Reson Med, 2018, 80(2): 685-695.
[15] Trout A T, Anupindi S A, Gee M S, et al. Normal liver stiffness measured with MR elastography in children [J]. Radiology, 2020, 297(3): 663-669.
[16] Sawh M C, Newton K P, Goyal N P, et al. Normal range for MR elastography measured liver stiffness in children without liver disease [J]. J Magn Reson Imaging, 2020, 51(3): 919-927.
[17] Joo J Y, Yoo I H, Yang H R. Serologic biomarkers for hepatic fibrosis in obese children with nonalcoholic steatohepatitis [J]. Pediatr Gastroenterol Hepatol Nutr, 2024, 27(4): 236-245.
[18] Liao Y, Wang L, Liu F, et al. Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: a bibliometric analysis [J]. Front Endocrinol (Lausanne), 2023, 14: 1078149.
[19] Ruiz De Morales J M G, Puig L, Daudén E, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies [J]. Autoimmun Rev, 2020, 19(1): 102429.
[20] Duan Y, Luo J, Pan X, et al. Association between inflammatory markers and non-alcoholic fatty liver disease in obese children [J]. Front Public Health, 2022, 10: 991393.
[21] Riccio S, Melone R, Vitulano C, et al. Advances in pediatric non-alcoholic fatty liver disease: from genetics to lipidomics [J]. World J Clin Pediatr, 2022, 11(3): 221-238.
[22] Shabalala S C, Dludla P V, Mabasa L, et al. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling [J]. Biomed Pharmacother, 2020, 131: 110785.
[23] Mohamed A A, Sabry S, Abdallah A M, et al. Circulating adipokines in children with nonalcoholic fatty liver disease: possible noninvasive diagnostic markers [J]. Ann Gastroenterol, 2017, 30(4): 457-463.
[24] Jiménez-cortegana C, García-galey A, Tami M, et al. Role of leptin in non-alcoholic fatty liver disease [J]. Biomedicines, 2021, 9(7):762.
[25] Boyraz M, Cekmez F, Karaoglu A, et al. Serum adiponectin, leptin, resistin and RBP4 levels in obese and metabolic syndrome children with nonalcoholic fatty liver disease [J]. Biomark Med, 2013, 7(5): 737-745.
[26] Nobili V, Alisi A, Valenti L, et al. NAFLD in children: new genes, new diagnostic modalities and new drugs [J]. Nat Rev Gastroenterol Hepatol, 2019, 16(9): 517-530.
[27] Bǎlǎnescu A, Stan I, Codreanu I, et al. Circulating hsp90 isoform levels in overweight and obese children and the relation to nonalcoholic fatty liver disease: results from a cross-sectional study [J]. Dis Markers, 2019, (2019): 9560247.
[28] Qin Z W, Ren Q N, Zhang H X, et al. Development and validation of a novel non-invasive test for diagnosing nonalcoholic fatty liver disease in Chinese children [J]. World J Pediatr, 2024, 20(4): 413-421.
[29] Xing Y, Zhang P, Li X, et al. New predictive models and indices for screening MAFLD in school-aged overweight/obese children [J]. Eur J Pediatr, 2023, 182(11): 5025-5036.
[30] Lischka J, Schanzer A, Hojreh A, et al. A branched-chain amino acid-based metabolic score can predict liver fat in children and adolescents with severe obesity [J]. Pediatr Obes, 2021, 16(4): e12739.
[31] Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement [J]. Lancet Gastroenterol Hepatol, 2021, 6(10): 864-873.
[32] Sakurai Y, Kubota N, Yamauchi T, et al. Role of insulin resistance in MAFLD [J]. Int J Mol Sci, 2021, 22(8):4156-4156.
[33] Trochimczyk K, Flisiak-jackiewicz M, Bobrus-chociej A, et al. Biochemical and anthropometric indices of insulin resistance in obese and overweight children with metabolic dysfunction-associated fatty liver disease [J]. Med Sci Monit, 2024, 30: e943375.
[34] Lazo-de-la-vega-monroy M L, Preciado-puga M D, Ruiz-noa Y, et al. Correlation of the pediatric metabolic index with NAFLD or MAFLD diagnosis, and serum adipokine levels in children [J]. Clin Res Hepatol Gastroenterol, 2023, 47(6): 102137.
[35] Abdelhameed F, Kite C, Lagojda L, et al. Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD [J]. Curr Obes Rep, 2024, 13(3): 510-531.
[36] Becker R. Non-invasive cancer detection using volatile biomarkers: is urine superior to breath? [J]. Med Hypotheses, 2020, 143: 110060.
[37] Alkhouri N, Cikach F, Eng K, et al. Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children [J]. Eur J Gastroenterol Hepatol, 2014, 26(1): 82-87.